New treatments

This page will list articles and news about new cancer treatments approved in Canada.

ALECENSARO® (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer

Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer (May 2018)

First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada (May 2018)

Lynparza® (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status (May 2018)

Health Canada approves KISQALI™ for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy (May 2018)

Health Canada approves TECENTRIQ® (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (April 2018)

Health Canada Approves RITUXAN® Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia (March 2018)

Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF® (trifluridine and tipiracil tablets) for metastatic colorectal cancer (March 2018)